Latest Articles about BMY

Pediatric Approval for MDCO/BMY's Recothrom - Analyst Blog

Zacks Equity Research — Thu, 16 May 2013 00:27:04 Z

The Medicines Company ( MDCO ) recently gained US Food and Drug Administration (FDA) approval for the use of Recothrom in pediatric patients. The FDA expanded Recothrom's label following

Amgen to Set Up JV in China - Analyst Blog

Zacks Equity Research — Wed, 15 May 2013 01:05:29 Z

Amgen ( AMGN ) recently announced its intention to set up a joint venture (JV) in China with Zhejiang Beta Pharma Co., Ltd. The JV will focus on the commercialization of Amgen's

A Buyout Could Send This Leading Agriculture Stock Up 25%

mike-vodicka@streetauthority.com (Michael Vodicka) — Tue, 14 May 2013 20:30:00 Z

Buyouts can be one of the quickest ways for investors to score a big profit. Buyout companies are almost always purchased at a premium that can give shareholders a nice pop. And with the

Simcere Beats 1Q Earnings & Revenue Estimate - Analyst Blog

Zacks Equity Research — Fri, 10 May 2013 20:23:59 Z

Simcere Pharmaceutical Group ( SCR ) reported first quarter 2013 earnings of 9 cents per American Depositary Share (ADS) beating the Zacks Consensus Estimate by a penny. We note that each

In Danish Laboratories, Hope Looms Large for a Permanent HIV Cure

Valorie Sands — Wed, 08 May 2013 21:42:00 Z

So far HIV has eluded a permanent cure, yet many newly diagnosed patients can now control the virus with just one pill per day. Most lead relatively normal lives. In developing countries where

Good News for Bristol-Myers - Analyst Blog

Zacks Equity Research — Tue, 07 May 2013 00:23:33 Z

Bristol-Myers Squibb Company ( BMY ) recently received positive news from the US Food and Drug Administration (FDA) when the US regulatory authority approved the pharma major's HIV drug

Narrower-than-Expected Loss at Cadence - Analyst Blog

Zacks Equity Research — Mon, 06 May 2013 21:24:54 Z

Cadence Pharmaceuticals, Inc. ( CADX ) posted an adjusted net loss of 13 cents per share in the first quarter of 2013, narrower than the Zacks Consensus Estimate of a loss of 14 cents. The

This May Be The Best Pharmaceutical Stock for Income Investors

LisaSpringer@LisaSpringer.com (Lisa Springer) — Fri, 03 May 2013 17:30:00 Z

As an income investor, I feel like I've hit the trifecta when I find a low-risk stock that also has consistent dividend growth and a fantastic yield. The high-quality dividend stocks I look for

Stocks Market News for May 1, 2013 - Market News

Zacks Equity Research — Wed, 01 May 2013 18:36:01 Z

A strong rally in technology shares along with encouraging economic reports on the home front lifted major indices higher on Tuesday. Both the S&P 500 and the Nasdaq recorded their

A Look Ahead: This Week's ETFs to Watch

ETF Professor — Mon, 29 Apr 2013 01:28:16 Z

Last week was another fine one for U.S. stocks as the broader market fought off an array of data points that can only be considered mixed at best to again close higher. With last week's 1.4

Earnings Increase at The Medicines Co. - Analyst Blog

Zacks Equity Research — Sat, 27 Apr 2013 01:22:26 Z

The Medicines Company ( MDCO ) reported first quarter earnings of 24 cents per share, compared with the year-ago earnings of 14 cents per share. Including one-time items, the company

Company News for April 26, 2013 - Corporate Summary

Zacks Equity Research — Fri, 26 Apr 2013 18:26:54 Z

• Bristol Myers Squibb Co. (NYSE: BMY ) reported first quarter earnings per share of $0.41, in line with the Zacks Consensus Estimate • Dominion

Stocks Survive Once Again

Minyanville Staff — Fri, 26 Apr 2013 01:15:00 Z

Stocks rallied nicely early in the day, but turned downward in the afternoon on news that the German Bundesbank rejected the OMT bond purchasing program out of risk concerns. The morning joy

Gilead Reports Encouraging HCV Data - Analyst Blog

Zacks Equity Research — Thu, 25 Apr 2013 03:10:53 Z

Gilead Sciences, Inc. ( GILD ) recently announced detailed results from four phase III studies (NEUTRINO, FISSION, POSITRON and FUSION) which evaluated its candidate sofosbuvir (formerly

Pre-Market Earnings Report for April 25, 2013 : XOM, MMM, MO, COP, BMY, OXY, UPS, CL, CELG, BIIB, DOW, D

NASDAQ.com News — Thu, 25 Apr 2013 00:00:04 Z

The following companies are expected to report earnings prior to market open on 04/25/2013. Visit our Earnings Calendar for a full list of expected earnings releases. Exxon Mobil Corporation